Table 3:
Features of secondary prevention of cervical cancer
| Countries | National screening program for cervical cancer | Type of screening | Primary screening test | Target age range (yr) | Quality assurance program | Active invitation to screening | Screening interval (yr) | Referral system | Coverage ever screened (%)/Year |
|---|---|---|---|---|---|---|---|---|---|
| Malaysia | Yes | Opportunistic | Cytology (pap smear) HPV test (available in 4 states) | 30–65 | No | No | 3 | Yes | 54 (2019) |
| Thailand | Yes | Organized | Cytology (pap smear)/VIA | 30–60 | Yes | No | 5 | Yes | 77 (2019) |
| Iran | Yes | Organized | HPV test | 30–49 | No | No | 5 | Yes | 49 (2019) |
| Kenya | Yes | Opportunistic | VIA/VILI HPV test | 25–49 ≥ 30: HPV | No | No | 5 | Yes | 17 (2019) |
| Argentina | Yes | Organized | HPV test | 25–65 | Yes | Yes | 5 | Yes | 89 (2019) |
| Ukraine | Yes | Opportunistic | Cytology | 18–65 | No | No | 1 | Yes | 62 (2019) |
Source: World Health Organization - Cervical Cancer Country Profiles, 2021